| Drug Type Chemical drugs | 
| Synonyms | 
| Target | 
| Action antagonists | 
| Mechanism CCR1 antagonists(C-C chemokine receptor type 1 antagonists), CCR3 antagonists(C-C chemokine receptor type 3 antagonists), CCR5 antagonists(C-C chemokine receptor type 5 antagonists) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Breast Cancer | Preclinical | United States  | 16 Apr 2023 | 





